Research graph
References from Attributing benefit and harm in clinical practice: medication burden, causality, and pharmacovigilance. Local targets link to admitted publications; unresolved targets remain external evidence.
Immediate-release vs. prolonged-release lithium formulations in bipolar disorder: a 2-year comparative study.
10.1097/yic.0000000000000584 · 2026 · External reference
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies.
10.1177/20451253231163682 · 2023 · External reference
Postictal psychosis in epilepsy: a clinicogenetic study.
10.1002/ana.26174 · 2021 · External reference
Medication review in hospitalised patients to reduce morbidity and mortality.
2023 · External reference
Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks.
10.1097/yic.0000000000000595 · 2026 · External reference
Clinical impact of medication review and deprescribing in older inpatients: a systematic review and meta-analysis.
10.1111/jgs.19035 · 2024 · External reference
Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations.
10.1097/yic.0000000000000636 · 2026 · External reference
Adverse outcomes of polypharmacy in older people: systematic review of reviews.
10.1016/j.jamda.2019.10.022 · 2020 · External reference
Anticholinergic drug burden and delirium: a systematic review.
10.1016/j.jamda.2020.04.019 · 2021 · External reference
Benzodiazepines and postoperative delirium: should we be as cautious as we are?
10.1016/j.bja.2023.07.004 · 2023 · External reference
The evolving role of disproportionality analysis in pharmacovigilance.
10.1080/14740338.2024.2368817 · 2024 · External reference
The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration.
10.1007/s40264-024-01423-7 · 2024 · External reference
The relationship between psychiatric symptoms and the use of levetiracetam in people with epilepsy.
10.1177/00912174231206056 · 2024 · External reference
Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial.
10.1001/jamapsychiatry.2025.2332 · 2025 · External reference
Treatment adherence rates across different psychiatric disorders and settings: findings from a large patient cohort.
10.1097/yic.0000000000000557 · 2025 · External reference
Lithium side effects and toxicity: prevalence and management strategies.
10.1186/s40345-016-0068-y · 2016 · External reference
Delirium and incident dementia in hospital patients in New South Wales, Australia: retrospective cohort study.
10.1136/bmj-2023-077634 · 2024 · External reference
Association between the number of delirium-associated medications and postoperative delirium in older adults: a multicenter retrospective study.
10.1097/yic.0000000000000624 · 2026 · External reference
Target trial emulation: a framework for causal inference from observational data.
10.1001/jama.2022.21383 · 2022 · External reference
Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis.
10.1001/jamainternmed.2014.7779 · 2015 · External reference
Target trial emulation for observational studies – potential and pitfalls.
10.1056/nejmp2407586 · 2024 · External reference
Psychiatric assessment prior to and after switch from levetiracetam to brivaracetam.
10.1016/j.seizure.2024.02.022 · 2024 · External reference
Forced normalization: antagonism between epilepsy and psychosis.
10.1016/j.pediatrneurol.2017.02.007 · 2017 · External reference
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
10.1016/s2215-0366(21)00039-0 · 2021 · External reference
Psychiatric comorbidities in persons with epilepsy compared with persons without epilepsy: a systematic review and meta-analysis.
10.1001/jamaneurol.2024.3976 · 2025 · External reference
Electronic health record intervention and deprescribing for older adults: a randomized clinical trial.
10.1001/jama.2025.26967 · 2026 · External reference
Impact of long-acting injectable aripiprazole on the concomitant medication and antipsychotic polypharmacy: a retrospective, observational study of 127 patients with psychosis.
10.1097/yic.0000000000000492 · 2024 · External reference
Psychiatric and behavioural side effects of antiseizure medications in epilepsy.
10.1007/s00415-025-13591-2 · 2025 · External reference
Lithium therapy and its interactions.
10.18773/austprescr.2020.024 · 2020 · External reference
Anticholinergic burden and cognitive function in psychosis: a systematic review and meta-analysis.
10.1176/appi.ajp.20240260 · 2025 · External reference
Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine.
10.1097/yic.0000000000000504 · 2025 · External reference
A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia.
10.1093/ijnp/pyab071 · 2022 · External reference
Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis.
10.1001/jamapsychiatry.2025.0679 · 2025 · External reference
Assessing treatment adherence in psychiatry: a comparison of clinical judgment and therapeutic drug monitoring in acute care.
10.1097/yic.0000000000000610 · 2026 · External reference
Effectiveness and safety of long-acting aripiprazole 960 mg: preliminary findings from a prospective real-world observational study.
10.1097/yic.0000000000000635 · 2026 · External reference
Psychiatric effects of GLP-1 receptor agonists: a systematic review of emerging evidence.
10.1111/dom.70198 · 2026 · External reference
Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
10.1080/14737175.2024.2313550 · 2024 · External reference
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.
10.1016/s0140-6736(21)01997-8 · 2022 · External reference
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator-blinded, randomised controlled trial in Australia.
10.1016/s2215-0366(25)00129-4 · 2025 · External reference
Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.
10.1097/yic.0000000000000632 · 2026 · External reference
Long-term clinical outcomes of delirium after hospital discharge: a systematic review and meta-analysis.
10.1093/ageing/afaf188 · 2025 · External reference
Psychosis and schizophrenia among patients with epilepsy: a systematic review and meta-analysis.
10.1016/j.eplepsyres.2024.107452 · 2024 · External reference
Disease relapse, all-cause mortality, and adverse events associated with long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia in Hong Kong: a population-based within-subject analysis.
10.1016/s2215-0366(25)00268-8 · 2025 · External reference
Levetiracetam, perampanel, and the issue of aggression: a self-report study.
10.1016/j.yebeh.2021.107806 · 2021 · External reference
Not all antipsychotic polypharmacy is the same.
10.1097/yic.0000000000000629 · 2026 · External reference
